Evaluation of Serum Galectin- 3 Levels in Preeclampsia at Term

Authors

  • Sumaya Q. Muhammed Azadi Teaching Hospital
  • Esraa A. Mohammed University of Kirkuk - College of medicine
  • Salih Ibrahem University of Kirkuk

DOI:

https://doi.org/10.25130/mjotu.29.2023.1.50-65

Keywords:

Pre-eclampsia; Galectin-3; Severity; Term; Pregnancy

Abstract

Background  Pre-eclampsia is a disorder of vascular endothelial dysfunction and vasospasm that occurs after 20 weeks of pregnancy and may occur up to 4–6 weeks after pregnancy. It is defined clinically by hypertension and proteinuria with or without pathological edema. Galectin-3 is expressed in all types of immune cells and organs in human tissues and plays an important role in many biological processes such as inflammatory responses, fibroids, intercellular adhesion, angiogenesis, apoptosis and cell differentiation.Aim of study  To evaluate Galectin-3 level in pre-eclampsia and to determine the association with severity of pre-eclampsiaPatients and method   A case-control study was conducted in the department of obstetrics and gynecology at Azadi Teaching Hospital / Kirkuk/ Iraq. The duration of study was eight months from 1st of February till 1st of October 2021.The study involved 90 patients, 60 preeclamptic women, and 30 (control group) with gestational age (37- 40). Patients were admitted to the hospital for following up their blood pressure, urine test for albumin, renal function test, liver function test were done, between 37-40 weeks gestational age of the pregnancy.ResultsGalectin-3 was significantly higher among pregnant women with severe preeclampsia in comparison to mild pre-eclampsia and control groups (p=0.0001), while no significant correlation in the mean Galectin-3 between normal and mild preeclampsia (P=0.92). Conclusion: Serum Galectin- 3 is a marker for diagnosis of pre-eclampsia and its severity

Downloads

Published

2023-06-30

Issue

Vol. 29 No. 1 (2023): Vol. 29 No.1 (2023)

Section

Articles

License

Copyright (c) 2024 THIS IS AN OPEN ACCESS ARTICLE UNDER THE CC BY LICENSE http://creativecommons.org/licenses/by/4.0/

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The Medical Journal of Tikrit University is licensed under the Creative Commons Attribution 4.0 International License, which allows users to copy, create extracts, abstracts, and new works from the article, alter and revise the article, and make commercial use of the article (including reuse and/or resale of the article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made, and the licensor is not represented as endorsing the use made of the work. The authors hold the copyright for their published work on the MJTU website, while MJTU is responsible for appreciate citation of their work, which is released under CC-BY-4.0, enabling the unrestricted use, distribution, and reproduction of an article in any medium, provided that the original work is properly cited.